The US alpha emitters market is witnessing strong growth due to increasing adoption of targeted radiopharmaceutical therapies, advanced oncology infrastructure, and significant investments in nuclear medicine research. The presence of leading biotechnology and pharmaceutical companies, along with expanding clinical trials and favorable regulatory support for innovative cancer treatments,...